According to a recent article,“Behçet's disease is rare, with prevalence estimates varying from 0.12 to 7.5 per 100,000 in the United States and Eur ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing products for rare diseases, has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in Behçet’s ...

To view the full article, visit https://ibn.fm/lyFjD ...

The SGX945 proof of concept pilot study was an open-label study that enrolled 8 patients age 18 years or older with mild to ...

After a tremendous 2025 UFL season, a handful of star players have signed contracts with NFL teams. Here's who's on the move.

The NHL on July 1, just before noon ET, released the list of players who were restricted free agents under Group 2, unrestricted free agents under Groups 3 and 6, and unrestricted free agents by ...